» Articles » PMID: 37456566

Pediatric IBD Patients Show Medication and Disease Activity Dependent Changes in NK Cell and CD4 Memory T Cell Populations

Overview
Journal Front Pediatr
Specialty Pediatrics
Date 2023 Jul 17
PMID 37456566
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: CD4+ memory T cells facilitate long-termed adaptive immune responses while NK cells are predominately rapid effector cells with significant functions for both intestinal homeostasis and inflammation. We wanted to study both populations in health and pediatric inflammatory bowel disease (IBD) and correlate them with disease activity and medication.

Methods: We performed flow cytometric analyses of peripheral blood CD4 + CD45RO+ memory T cells and CD3-CD16 + CD56+ NK cells in 30 patients with IBD and 31 age-matched controls and correlated percentages of subsets with disease activity (PUCAI/PCDAI) and medication.

Results: We found a significant reduction of peripheral NK cells in overall IBD patients with both clinical remission and disease activity, which was even more pronounced in patients treated with azathioprine. Otherwise, circulating CD4+ memory T cell populations were significantly enhanced in active IBD compared to controls. Enhancement of memory T cells was particularly found in new onset disease and correlated with disease activity scores.

Discussion: Our single center cohort confirms previous results showing enhanced memory T cell populations in pediatric IBD patients, which correlate with disease activity scores. CD4+ memory T cells are a relevant pathogenic leukocyte population for disease development and perpetuation in IBD. In addition, we found a decrease of NK cells in IBD patients, which was pronounced by use of azathioprine. Surveillance of both cellular populations could possibly serve as biomarker for therapy control in pediatric IBD.

Citing Articles

Relationship between the risk of intestinal mucosal Epstein-Barr virus and/or cytomegalovirus infection and peripheral blood NK cells numbers in patients with ulcerative colitis: a cross-sectional study in Chinese population.

Tian Y, Dai J, Yang Y, Guo X, Wang W, Li F Front Microbiol. 2024; 15:1498483.

PMID: 39697654 PMC: 11652489. DOI: 10.3389/fmicb.2024.1498483.


"Deficiency in ELF4, X-Linked": a Monogenic Disease Entity Resembling Behçet's Syndrome and Inflammatory Bowel Disease.

Olyha S, OConnor S, Kribis M, Bucklin M, Uthaya Kumar D, Tyler P J Clin Immunol. 2024; 44(2):44.

PMID: 38231408 PMC: 10929603. DOI: 10.1007/s10875-023-01610-8.

References
1.
Tindemans I, Joosse M, Samsom J . Dissecting the Heterogeneity in T-Cell Mediated Inflammation in IBD. Cells. 2020; 9(1). PMC: 7016883. DOI: 10.3390/cells9010110. View

2.
Hedin C, McCarthy N, Louis P, Farquharson F, McCartney S, Taylor K . Altered intestinal microbiota and blood T cell phenotype are shared by patients with Crohn's disease and their unaffected siblings. Gut. 2014; 63(10):1578-86. DOI: 10.1136/gutjnl-2013-306226. View

3.
ROMAN L, Manzano L, de la Hera A, Abreu L, Rossi I, Alvarez-Mon M . Expanded CD4+CD45RO+ phenotype and defective proliferative response in T lymphocytes from patients with Crohn's disease. Gastroenterology. 1996; 110(4):1008-19. DOI: 10.1053/gast.1996.v110.pm8612987. View

4.
van Unen V, Ouboter L, Li N, Schreurs M, Abdelaal T, Kooy-Winkelaar Y . Identification of a Disease-Associated Network of Intestinal Immune Cells in Treatment-Naive Inflammatory Bowel Disease. Front Immunol. 2022; 13:893803. PMC: 9260579. DOI: 10.3389/fimmu.2022.893803. View

5.
Bishu S, El Zaatari M, Hayashi A, Hou G, Bowers N, Kinnucan J . CD4+ Tissue-resident Memory T Cells Expand and Are a Major Source of Mucosal Tumour Necrosis Factor α in Active Crohn's Disease. J Crohns Colitis. 2019; 13(7):905-915. PMC: 6939878. DOI: 10.1093/ecco-jcc/jjz010. View